Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
Danka Sinikovic ZebicAngelina TjokrowidjajaKatherine Elizabeth FrancisMichael L FriedlanderVal GebskiAlain LortholaryFlorence JolyAnnette HasenburgMansoor MirzaUrsula DenisonSabrina Chiara CecereAnnamaria FerreroEric Pujade-LauraineChee Khoon LeePublished in: British journal of cancer (2023)
Approximately 2 in 3 women with PSROC have RECIST PD but not CA-125 PD by GCIG criteria. Monitoring CA-125 levels alone is not reliable for detecting PD. Further research is required to investigate the survival impact of local therapy in radiological detected early asymptomatic PD.